ArticleScientific reports2025
Primary sjögren's syndrome among patients with cerebral infarction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular Stent-Assisted Intracranial Lysis for Acute Middle Cerebral Artery Occlusion in a Young Woman with Primary Sjögren's Syndrome: Case Report.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To investigate the clinical features, treatment, and outcomes in cerebral infarction (CI) patients with Sjögrens syndrome (pSS) for novel disease management strategies. A total of 27 patients diagnosed with CI with pSS were divided into the treatment group (12 patients) and non-treatment group (15 patients) according to whether they were treated for pSS in the acute and secondary prevention stage of CI. The related clinicopathological information including age, gender, medical history, experimental data, clinical manifestations, imaging data, treatment, functional recovery and recurrences were retrospectively analyzed. The clinical manifestations of 27 CI patients with pSS varied widely. There were also no significant differences in age, gender, traditional high-risk factors of CI, previous history, experimental data, and short-term nerve functional recovery between the two groups (p > 0.05). After 1 year of treatment, timely treatment of pSS can significantly improve the prognosis, the favorable prognosis (modified Rankin scale ≤ 2) of the treatment and non-treatment groups were 83.3% and 40.0% respectively. The recurrence rate of CI was 0% in the treatment group but 33.3% in the non-treatment group. Compared to the no treatment group. The odds of achieving a favorable prognosis in the treatment group were 7.5 times higher than in the non-treatment group (OR = 7.5, 95% CI: 1.195-47.1). the adjusted odds ratio was 0.113 (95% CI: 0.002-1.214). This indicates an 89% reduction in recurrence odds with treatment. PSS screening is necessary for CI patients. Moreover, prompt pSS treatment administered during the acute and secondary prevention stage of CI with pSS can promote neurologic functional independence and reduce the risk of CI recurrent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.